Len Seymour
Professor of Gene Therapies
- Director of Clinical Pharmacology
Research Summary
The aim of our research is to design and develop innovative cancer killing viruses and oncolytic vaccines.
Biography
Len Seymour was the Founding President of the British Society for Gene and Cell Therapy, Secretary and Trustee of the European Society of Gene and Cell Therapy and is an Executive Council Member of the International Society for Cell and Gene Therapy of Cancer.
He is Chair of the Scientific Advisory Board of the Chronic Granulomatous Disorder Research Trust, and also chairs the Scientific Advisory Board of the Muscular Dystrophy Consortium.
Len is the Course Director of the part-time MSc in Experimental and Translational Therapeutics, offered by the Department, in conjunction with the Department for Continuing Education.
GROUP MEMBERS
Hena Khalique - Postdoctoral Researcher
Ahmet Hazini - Postdoctoral Researcher
Richard Baugh - Postdoctoral Researcher and Laboratory Manager
Flurin Caviezel - DPhil Student
Arthur Dyer - Laboratory Manager
Mahnoor Nadeem - DPhil Student
Weiheng Su - DPhil Student
Peter Wan - DPhil Student
Henry Brigden - DPhil Student
Emma Paige - DPhil Student
Kate Friesen - DPhil student
Fernando Gallardo - DPhil Student
Members of the Seymour Group
GROUP ALUMNI & NEXT DESTINATIONS
Dr Aliaa Alimoudi - Researcher, King Abdulaziz University Faculty of Medicine
Egon Jacobus Ambuludi - Theolytics, Oxford
Dr Ryan Cawood - Founder and CEO of Oxford Genetics
Dr Suet Lin Chia - Senior Lecturer, Universiti Putra Malaysia, Department of Microbiology
Dr Thomas Hills - Doctor in New Zealand
Dr Viviana Cobos Jimenez - Post Doctoral Research Associate, College of Veterinary Medicine, University of Georgia
Dr Lisa Cooper - Senior Scientist, Oxford Biomedica
Gray Kueberuwa - Postdoctoral Researcher, Cancer Research UK Manchester Institute
Sophie Owen - PhD Tropical Medicine, Liverpool School of Tropical Medicine
Fnu Iris - Mayo Graduate School of Biomedical Sciences
Joshua Freedman - Theolytics, Oxford
Philip Jakeman - MacrophOx
Margaret Duffy - Theolytics, Oxford
Eleanor Scott - Theolytics, Oxford
Tzveta Pokrovska - Charing Cross Hospital, London
William Taverner - Theolytics, Oxford
Abhishek Srivastava - Oxford Genetics
Arthur Dyer – Astra Zeneca
Sally Frost - Theolytics
Key publications
-
An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells.
Journal article
Freedman JD. et al, (2018), Cancer Res, 78, 6852 - 6865
-
Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators.
Journal article
Dyer A. et al, (2017), Mol Ther Oncolytics, 4, 18 - 30
-
Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.
Journal article
Freedman JD. et al, (2017), EMBO Mol Med, 9, 1067 - 1087
-
Antagonism of Glycolysis and Reductive Carboxylation of Glutamine Potentiates Activity of Oncolytic Adenoviruses in Cancer Cells.
Journal article
Dyer A. et al, (2019), Cancer Res, 79, 331 - 345
-
Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens.
Journal article
Lynn GM. et al, (2020), Nat Biotechnol, 38, 320 - 332
Recent publications
-
Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells
Journal article
Baugh R. et al, (2024), Journal for ImmunoTherapy of Cancer, 12, e008460 - e008460
-
The British Society for Gene and Cell Therapy at 20 (2003–2023)
Journal article
Seymour L. et al, (2024), Human Gene Therapy, 35, 5 - 8
-
Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?
Journal article
Wan PK-T. et al, (2023), J Immunother Cancer, 11
-
Optogenetically Engineered Neurons Differentiated from Human SH-SY5Y Cells Survived and Expressed ChR2 in 3D Hydrogel
Journal article
Lee S-Y. et al, (2022), Biomedicines, 10, 1534 - 1534
-
Self-attenuating adenovirus enables production of recombinant adeno-associated virus for high manufacturing yield without contamination.
Journal article
Su W. et al, (2022), Nat Commun, 13